Logo XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Equipment
  3. aptamer target binding
Show results for
Products
Services

Companies

Articles

Refine by
Locations

  • USA
  • Canada
  • Europe

  • Africa
  • Asia & Middle East
  • Australasia
  • Latin America
  • North America
Brands

  • pure biologics
Applications

  • Highly customized aptamer discovery solutions for aptamers in neurological disease sector
  • Highly customized aptamer discovery solutions for hot areas for aptamers sector

Aptamer Target Binding Equipment & Supplies

3 equipment items found

Aptamer Affinity Determination Technology

Aptamer Affinity Determination Technology

by:Base Pair Biotechnologies, Inc.   based inPearland, TEXAS (USA)
The determination of aptamer-target binding characteristics is an important tool in the aptamer discovery process. Affinity determination with Bio-Layer Interferometry (BLI) can be used to select aptamer candidates for specific downstream applications, identify matched aptamer pairs, and ...
CONTACT SUPPLIER

Pure Biologics - Model PB005 AptaMG - Therapeutic Medical Device

Pure Biologics - Model PB005 AptaMG - Therapeutic Medical Device

by:Pure Biologics SA   based inWroclaw, POLAND
Myasthenia gravis (MG) is an autoimmune condition classified as a rare disease. Accordingly, myasthenic patients lack effective treatment options, as this rare disease is not a primary interest of the pharmaceutical industry. However, considerable social and institutional support exists for the development of new therapies to treat rare diseases. The PB005 (AptaMG) project aims to develop a novel ...
CONTACT SUPPLIER

Pure Biologics - Model PB002 AptaPheresis - Therapeutic Medical Device

Pure Biologics - Model PB002 AptaPheresis - Therapeutic Medical Device

by:Pure Biologics SA   based inWroclaw, POLAND
Neuromyelitis optica (NMO) is an neurological autoimmune condition classified as a rare disease. Because of this classification, NMO lacks effective treatment options, since it is not of primary interest to the pharmaceutical industry. However, considerable social and institutional support exists for developing new therapies for such rare diseases. The PB002 (AptaPheresis) project aims to ...
CONTACT SUPPLIER
  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About XPRT Media

XPRT is a global industry marketplace and information resource. Online product catalogs, news, articles, events, publications & more.


  • FAQs
  • Company sitemap
  • Category sitemap
XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
Medical XPRT